May 3, 2018 04:15 PM EDT
R&D
Pharma

Mer­ck dou­bles down on Mod­er­na's mR­NA can­cer vac­cines, pay­ing $125M to part­ner on KRAS shared anti­gen strat­e­gy

John Carroll

Editor & Founder

Mer­ck and its R&D chief Roger Perl­mut­ter are bet­ting big on their re­la­tion­ship with Mod­er­na, pay­ing $125 mil­lion for a chunk of Se­ries H eq­ui­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times